{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:53:53Z","timestamp":1778878433353,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,26]]},"DOI":"10.7759\/cureus.83035","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:23:28Z","timestamp":1745677408000},"source":"Crossref","is-referenced-by-count":2,"title":["Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India"],"prefix":"10.7759","author":[{"given":"Arijit","family":"Nag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baalamurugan","family":"KT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeevan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouriyo","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibakar","family":"Podder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debranjani","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saswata","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumyadip","family":"Chatterji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asish","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyash","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-023-01654-1","article-title":"Cytomegalovirus reactivation as a risk factor for all-cause mortality in children undergoing hematopoietic stem cell transplantation: experience over two decades from a tertiary referral center in India","volume":"40","author":"Chakraborty S","year":"2024","unstructured":"Chakraborty S, Swaminathan VV, Ganesan K, et al.. Cytomegalovirus reactivation as a risk factor for all-cause mortality in children undergoing hematopoietic stem cell transplantation: experience over two decades from a tertiary referral center in India. Indian J Hematol Blood Transfus. 2024, 40:91-6. 10.1007\/s12288-023-01654-1","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.62621","article-title":"The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data","volume":"18","author":"Han SH","year":"2021","unstructured":"Han SH, Yoo SG, Do Han K, La Y, Kwon DE, Lee KH. The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data. Int J Med Sci. 2021, 18:3333-41. 10.7150\/ijms.62621","journal-title":"Int J Med Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.01.082","article-title":"Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide","volume":"30","author":"Chor\u00e3o P","year":"2024","unstructured":"Chor\u00e3o P, Henriques M, Villalba M, et al.. Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide. Transplant Cell Ther. 2024, 30:538.e1-10. 10.1016\/j.jtct.2024.01.082","journal-title":"Transplant Cell Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman P","year":"2011","unstructured":"Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011, 25:151-69. 10.1016\/j.hoc.2010.11.011","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1871","article-title":"Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality","volume":"73","author":"Akahoshi Y","year":"2021","unstructured":"Akahoshi Y, Kimura SI, Inamoto Y, et al.. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2021, 73:e620-8. 10.1093\/cid\/ciaa1871","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Allaw F","year":"2023","unstructured":"Allaw F, Haddad SF, Zakhour J, Kanj SS. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants. Int J Antimicrob Agents. 2023, 62:106860. 10.1016\/j.ijantimicag.2023.106860","journal-title":"Int J Antimicrob Agents"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh M","year":"2011","unstructured":"Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011, 121:1673-80. 10.1172\/JCI45449","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: first global approval","volume":"78","author":"Kim ES","year":"2018","unstructured":"Kim ES. Letermovir: first global approval. Drugs. 2018, 78:147-52. 10.1007\/s40265-017-0860-8","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-124739","article-title":"Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients","volume":"74","author":"Saullo JL","year":"2023","unstructured":"Saullo JL, Miller RA. Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients. Annu Rev Med. 2023, 74:89-105. 10.1146\/annurev-med-042921-124739","journal-title":"Annu Rev Med"},{"key":"ref10","unstructured":"Recommendations of the SEC (antimicrobial & antiviral) made in its 04th\/24 meeting held on 10.04.2024 at CDSCO (HQ), New Delhi. (2024). https.\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Antimicrobial%20&%2...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty FM","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, et al.. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017, 377:2433-44. 10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu LW","year":"2022","unstructured":"Liu LW, Yn A, Gao F, et al.. Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transplant Cell Ther. 2022, 28:510.e1-9. 10.1016\/j.jtct.2022.05.020","journal-title":"Transplant Cell Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010966","article-title":"Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant","volume":"7","author":"Lin A","year":"2023","unstructured":"Lin A, Brown S, Chinapen S, et al.. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant. Blood Adv. 2023, 7:7153-60. 10.1182\/bloodadvances.2023010966","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty FM","year":"2020","unstructured":"Marty FM, Ljungman PT, Chemaly RF, et al.. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020, 20:1703-11. 10.1111\/ajt.15764","journal-title":"Am J Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo D","year":"2024","unstructured":"Russo D, Schmitt M, Pilorge S, et al.. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024, 11:127-35. 10.1016\/S2352-3026(23)00344-7","journal-title":"Lancet Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356230-bioequivalent-letermovir-usage-for-prophylaxis-in-haploidentical-stem-cell-transplantation-at-high-risk-of-cmv-reactivation-a-report-of-two-cases-from-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:23:29Z","timestamp":1745677409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356230-bioequivalent-letermovir-usage-for-prophylaxis-in-haploidentical-stem-cell-transplantation-at-high-risk-of-cmv-reactivation-a-report-of-two-cases-from-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.83035","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,26]]}}}